
BioArctic and Mesenkia partner to develop new antibody treatment for aggressive brain cancer glioblastoma.
BioArctic AB and Mesenkia Therapeutics have entered a research collaboration to develop a novel antibody-based treatment for glioblastoma, a highly aggressive brain cancer with limited treatment options. The partnership combines BioArctic's BrainTran...

